PremiumRatingsBuy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile Promising Growth Potential for Cartesian Therapeutics: Buy Rating Affirmed by Analyst Gil Blum Promising Potential of Cartesian Therapeutics’ Descartes-08 in gMG Treatment: A Buy Recommendation PremiumRatingsBuy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress Cartesian price target lowered to $40 from $45 at H.C. Wainwright Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger PremiumThe FlyCartesian Therapeutics sees cash runway into mid-2027 Cartesian Therapeutics announces employment inducement grant Is RNAC a Buy, Before Earnings? 
